FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Gastrointestinal Drugs Advisory Committee (GIDAC) Meeting
May 19, 2023

QUESTIONS

---

1. **DISCUSSION**: Discuss the strength of the available efficacy data on the histopathologic endpoint, a surrogate endpoint that is reasonably likely to predict clinical benefit, in nonalcoholic steatohepatitis (NASH) patients with Stage 2 or 3 fibrosis treated with obeticholic acid (OCA) 25 mg.

2. **DISCUSSION**: Based on the data presented concerning cholestatic drug-induced liver injury (DILI) in OCA 25 mg-treated patients, discuss:
   a. Whether periodic liver enzyme monitoring could adequately mitigate the risk of DILI
   b. The frequency of such monitoring
   c. What stopping criteria should be developed to aid clinicians' decisions to discontinue treatment

3. **VOTE**: Given the available efficacy and safety data, do the benefits of OCA 25 mg outweigh the risks in NASH patients with Stage 2 or 3 fibrosis?

4. **VOTE**: Clinical outcome events in patients enrolled in Trial 747-303 will continue to be captured to evaluate clinical benefit in support of a future application for traditional approval. At present, which of the following would you recommend:

   a. Approval of OCA 25 mg at this time, under the accelerated (approval) pathway, based on efficacy data on a histopathologic surrogate and available clinical safety data;

   b. Defer approval until clinical outcome data from Trial 747-303 are submitted and reviewed, at which time the traditional approval pathway could be considered.